Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings.
J Eur Acad Dermatol VenereolMay 23, 2026 (epub)
Richard B Warren, Melinda Gooderham, Edward Lain et al.
✦ AI-curated · Sources linked
In 30 seconds
The ICONIC-TOTAL study, a multicenter randomized controlled trial, evaluated the efficacy and safety of icotrokinra in 311 participants with high-impact site plaque psoriasis over one year. Results showed durable clearance rates, with 67%-70% achieving overall skin clearance (IGA 0/1) and significant improvements in nail psoriasis (62% improvement in mNAPSI) by Week 52, with no safety concerns reported.
Key findings
- 67%-70% of icotrokinra participants achieved overall skin clearance (IGA 0/1) by Week 52.
- 85%-90% achieved clearance in genital psoriasis (sPGA-G 0/1) by Week 52.
- 62% improvement in nail psoriasis (mNAPSI) from Week 16 to Week 52.
- No increase in adverse event rates compared to placebo through Week 52.
Why it matters
The study highlights icotrokinra's potential as an effective oral treatment for high-impact site psoriasis, addressing a significant unmet need in managing this challenging condition. Its favorable safety profile further supports its use in clinical practice.